Amgen & Sandoz v. Mankind Pharma — Federal Circuit Appeal, 11 Apremilast Patents
Amgen and Sandoz brought a multi-defendant patent infringement action covering eleven patents protecting apremilast (Otezla) — its composition, solid forms, and PDE4-inhibition treatment methods — against a coalition of ten generic pharmaceutical manufacturers. The Federal Circuit's docket records an AFFIRMED order; the recorded basis of termination is Appeal Dismissed. The case ran 520 days from filing to closure.
Eleven apremilast patents, ten generics, one Federal Circuit ruling
Filed 15 November 2021 at the Court of Appeals for the Federal Circuit (Case No. 22-1150), this appeal pitted branded-drug interests — Amgen, Inc. and Sandoz, Inc. — against a broad coalition of generic manufacturers including Mankind Pharma, Aurobindo Pharma, Actavis, Heritage Pharmaceuticals, Emcure, Prinston, Macleods, Glenmark, MSN Laboratories, and Torrent Pharmaceuticals. The asserted portfolio comprised eleven US patents covering apremilast's chemical composition, crystalline solid forms, synthesis methods, and PDE4-inhibition dosage titration regimens.
The recorded basis of termination for this case is 'Appeal Dismissed.' The docket order separately states 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED.' These two characterisations appear in the record without further explanation; the specific terms and procedural basis for the resolution are not further disclosed in the available record.
The case closed 19 April 2023, approximately 520 days after filing — a duration consistent with a contested multi-party Federal Circuit briefing cycle. What drove the specific recorded basis of termination, as distinct from the AFFIRMED order language, is not explained in the public record. The disposition of the underlying district court proceedings and any remaining ANDA pathway implications for the defendant generics are not detailed in the available record.
See Complete Case & Patent Analysis →Filing to Appeal Dismissed in 520 days
520 days — multi-defendant Federal Circuit appeal spanning roughly 17 months
US9872854 — apremilast composition, solid forms & PDE4 inhibition methods
Any company developing, formulating, or seeking to market a generic version of apremilast — or a structurally related PDE4 inhibitor — should conduct a thorough freedom-to-operate analysis against all eleven patents asserted in this case. This is particularly urgent for ANDA filers, biosimilar developers, or product teams working on crystalline solid forms or dose-titration regimens for inflammatory and dermatological indications.
Official order — verbatim text
The docket order states 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED,' indicating the Federal Circuit panel found no reversible error in the proceedings below. The recorded basis of termination is separately listed as 'Appeal Dismissed.' Both are reproduced from the public record; the available record does not explain the relationship between these two characterisations.
Federal Circuit ruling: what the AFFIRMED order means for both parties
What 'AFFIRMED' means at the Federal Circuit
An affirmance at the Federal Circuit means the appellate panel found no reversible error in the decision below. The lower court's ruling stands in full, and the appealing party's arguments — whether on claim construction, obviousness, or infringement — did not meet the standard required to overturn the decision. Note: the recorded basis of termination is 'Appeal Dismissed'; the order text states AFFIRMED. Both are reproduced here as-is from the public record.
No reversible error foundApremilast patent portfolio survives appellate challenge
For Amgen and Sandoz, an AFFIRMED outcome at the Federal Circuit reinforces the enforceability of the asserted apremilast patents against the named generic defendants. The generic manufacturers' challenge to the lower-court decision did not succeed at the appellate level, suggesting the patents' validity and/or infringement findings remain intact as against the parties to this appeal, based on the available record.
Portfolio enforceability reinforcedGeneric defendants' appellate path exhausted at this level
For the ten generic defendants — including Mankind Pharma, Aurobindo, Actavis, and Glenmark — the AFFIRMED order closes the Federal Circuit route of challenge. Further appellate options at this level are foreclosed. Any continued path to market for apremilast generics would need to rely on grounds not adjudicated in this appeal, or on Supreme Court certiorari — an avenue with a very high threshold. The specific commercial impact on their ANDA filings is not detailed in the public record.
Federal Circuit route closedStrengthened apremilast IP raises the bar for generic entry
An affirmance across eleven patents covering composition, solid forms, and treatment methods signals a broad and resilient IP position for apremilast. Generic manufacturers in the PDE4-inhibitor space face a higher bar for challenging this portfolio through appeals. Companies assessing freedom-to-operate around apremilast formulations, dosage titration regimens, or crystalline forms should factor this ruling into their risk analysis and design-around strategies.
High generic-entry barrier maintainedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Amgen, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Sandoz, Inc. | Company | Search in Eureka ↗ |
| Defendant | Mankind Pharma, Ltd. | Company | /Search in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | ACTAVIS LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Heritage Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Emcure Pharmaceuticals, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Prinston Pharmaceutical, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Macleods Pharmaceuticals, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Glenmark Pharmaceuticals Limited | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Laboratories Private, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Torrent Pharmaceuticals, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier Director | Attorney | Counsel for Amgen, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Amgen, Inc.Search in Eureka ↗ |
| Defendant counsel | David C. Kistler Esq. | Attorney | Counsel for Mankind Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | Blank Rome LLP | Law Firm | Representing Mankind Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in the apremilast and PDE4 inhibitor patent space
Forward-looking patent intelligence on Amgen and Sandoz's apremilast portfolio, generic challenger filings, and adjacent PDE4 inhibitor innovation activity.
Amgen's apremilast filing activity beyond the 11 asserted patents
Amgen's apremilast IP estate extends beyond the eleven patents litigated here. Monitoring Amgen's continuation and divisional filings in the apremilast family — particularly claims directed at new formulations, patient populations, or combination therapies — can reveal where the next enforcement perimeter is being built and where design-around space may narrow further.
Amgen apremilast portfolio expansionPDE4 inhibitor filing trends post-apremilast patent affirmance
PDE4 inhibition remains an active R&D domain, with filing activity from competitors targeting structurally differentiated compounds, novel indications (atopic dermatitis, COPD, IBD), and next-generation oral formulations. A Federal Circuit affirmance on this scale may accelerate competitor filings in adjacent claim spaces not covered by the apremilast portfolio.
PDE4 inhibitor filing trendsGeneric defendants' own patent activity in the PDE4 space
Several defendants — including Glenmark, Aurobindo, and Torrent — maintain their own active patent portfolios in pharmaceutical formulation and process chemistry. Tracking their filings in PDE4-adjacent chemistry and crystalline form technologies can reveal whether they are investing in differentiated IP as an alternative to the blocked apremilast ANDA pathway, or pivoting to next-generation targets.
Generic pharma PDE4 filingsDesign-around opportunities near the apremilast solid-form claims
The solid-form and dosage-titration patents (including US10092541 and US9018243) represent some of the later-expiring protection in this estate. White-space analysis around polymorphic forms not claimed by Amgen, alternative crystallisation processes, or modified-release delivery mechanisms may reveal viable non-infringing pathways for generic and novel-drug developers targeting the same clinical indications.
Apremilast solid-form white spaceSimilar Federal Circuit appeals involving multi-patent ANDA pharmaceutical challenges
Explore Federal Circuit cases involving multi-patent ANDA challenges to small-molecule drug portfolios, including PDE4 inhibitors and branded pharma enforcement actions.
What this case signals for the apremilast and PDE4 inhibitor IP landscape
A Federal Circuit affirmance across eleven patents sets a high bar for generic ANDA challengers in the PDE4-inhibitor space.
Eleven-patent stack creates a dense enforcement perimeter around apremilast
Asserted patents span chemical composition, crystalline solid forms, synthesis, and method-of-treatment claims — a layered portfolio strategy that is difficult to design around comprehensively. Any generic seeking market entry must address each layer. IP teams monitoring this space should map claim scope across all eleven patents before assessing FTO.
Multi-defendant coordination signals organised ANDA challenger coalitions
Ten generic defendants — spanning US, Indian, and European companies — coordinated against this portfolio in a single appeal. This suggests shared litigation resources and aligned invalidity arguments. Brand-side IP teams should anticipate coalition-style challenges when their portfolios cover blockbuster small-molecule drugs with multiple ANDA filers.
Amgen v Mankind — key questions answered
Amgen and Sandoz asserted eleven US patents covering apremilast, including US9872854, US6962940, US10092541, US9018243, US7208516, US8455536, US7427638, US8802717, US7893101, US7659302, and US8093283. The patents collectively protect apremilast's chemical composition, crystalline solid forms, synthesis methods, and PDE4-inhibition dosage titration regimens.
The docket order states 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED.' The recorded basis of termination is separately listed as 'Appeal Dismissed.' Both characterisations appear in the available record; no further explanation of the relationship between them is disclosed in the public record.
Ten generic pharmaceutical manufacturers were named as defendants: Mankind Pharma Ltd., Aurobindo Pharma USA Inc., Aurobindo Pharma Ltd., Actavis LLC, Heritage Pharmaceuticals Inc., Emcure Pharmaceuticals Ltd., Prinston Pharmaceutical Inc., Macleods Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., MSN Laboratories Private Ltd., and Torrent Pharmaceuticals Ltd.
An AFFIRMED order at the Federal Circuit means the lower court's findings — on validity, infringement, or both — survived appellate scrutiny. For the named generic defendants, the Federal Circuit route of challenge is exhausted. Their ability to obtain ANDA approval and launch generic apremilast products depends on factors not fully disclosed in this public record, but the ruling reinforces the enforceability of the asserted patents against these specific parties.
Any company developing a structurally related PDE4 inhibitor, a generic apremilast formulation, or a product targeting the same inflammatory indications (psoriasis, psoriatic arthritis, ankylosing spondylitis) should conduct a freedom-to-operate analysis against all eleven asserted patents. The Federal Circuit affirmance makes it more difficult to dismiss these patents as vulnerable, and solid-form and method claims may have later expiry dates than the base composition patent.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.